(CTN News) – An analyst who recently began covering Pfizer (NYSE: PFE) is telling investors now is the time to buy. According to Guggenheim analyst Vamil Divan in a report released last week, Pfizer is likely to be worth $36 per share. The closing price on Friday represented a gain of approximately 30%. In response […]

Go to Source
Author: AlishbaW